Background. Vemurafenib has been linked to dermatological adverse events in patients with melanoma, including an increased risk of rash, cutaneous squamous cell carcinoma, photosensitivity reaction and keratoacanthoma. However, there has been no systematic attempt to assess the dermatological toxicity data of vemurafenib associated with melanoma treatment. Aim. To evaluate the point prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma. Methods. Searches were conducted of the electronic databases PubMed and EMBASE and of conference abstracts published by the American Society of Clinical Oncology. Eligible studies included prospective clinical trials and expanded-access programmes (i.e. outside a clinical trial) of patients with melanoma assigned to vemurafenib treatment. Outcomes included prevalence of dermatological toxicities treated with vemurafenib. Statistical analyses were performed using the R2.8.1 meta package. Results. In total, 11 studies comprising 4197 patients were included in the metaanalysis. For patients assigned to vemurafenib, the overall prevalence of all-grade cutaneous squamous cell carcinoma (cSCC) was 18.00% (95% CI 12.00-26.00%), rash 45.00% (95% CI 34.00-57.00%), photosensitivity reaction (PR) 30.00% (95% CI 23.00-38.00%), keratoacanthoma (KA) 10.00% (95% CI 6.00-15.00%) and handfoot skin reaction (HFSR) 9.00% (95% CI 4.00-20.00%), while the prevalence of highgrade events was: cSCC 16.00% (95% CI 11.00-23.00%), rash 12.00% (95% CI 3.00-38.00%), PR 4% (95% CI 2.00-8.00%) and KA 6.00% (95% CI 5.00-7.00%). Conclusion. The most frequent dermatological toxicities associated with vemurafenib treatment in patients with melanoma were cSCC, rash, PR and KA. These data may be useful for estimation of the efficacy and safety of the drug during clinical treatment and for reducing the prevalence of adverse reactions to vemurafenib treatment in patients with melanoma.
Introduction
The global incidence of melanoma is increasing, with approximately 200 000 new cases and about 65 000 melanoma-associated deaths every year. Although metastatic melanoma has typically been associated with poor prognosis, with a mean survival rate of 15-60%, the therapeutic options have recently changed substantially. 1 New anticancer therapies targeting various kinases implicated in cancer progression are now accepted and used in clinical practice, and the prognosis of several cancers has been improved.
Activating BRAF (V600E) kinase mutations occur in about 7% of human malignancies and 60% of melanomas. 2 Vemurafenib is a synthetic oral BRAF inhibitor targeting growth signalling and angiogenesis, which has high selectivity and effectiveness in the clinical treatment of melanomas, and can inhibit BRAF activity at low concentrations. 3 The clinical benefits of vemurafenib were initially seen in randomized trials, which showed that vemurafenib could prolong the survival in patients with metastatic melanoma, and it is now a standard treatment option. In addition, vemurafenib has been found to have clinical benefits in other malignant diseases such as breast, urothelial and prostate cancer. 4 As vemurafenib enters wider clinical usage, it should be noted that it is not devoid of side effects, of which the most prominent are a large number of cutaneous adverse events (AEs). The most common dermatological AEs reported in clinical trials on vemurafenib include cutaneous squamous cell carcinoma (cSCC), rash, photosensitivity reaction (PR), keratoacanthoma (KA) and hand-foot skin reaction (HFSR). 5 It is important for physicians to recognize and manage the dermatological toxicities associated with vemurafenib because they can affect therapeutic efficacy and patients' quality of life, and can lead to infection, discomfort and some degree of mental distress for patients. Skin reactions may be alleviated with dose reduction and/or interruption but this will also reduce the efficiency of vemurafenib. Addiionally, it has beeen reported that the severity of skin toxicities correlates with the efficacy of the drug. 6 There is therefore a need to evaluate the characteristics and prevalence of dermatological toxic effects to allow early and adequate prevention and intervention.
We performed a meta-analysis to assess the prevalence of each of the dermatological toxicities associated with vemurafenib treatment in patients with melanoma, and to provide treatment recommendations for these symptoms.
Methods

Data sources
The electronic databases PubMed (1964 PubMed ( -2016 and EMBASE (1980 EMBASE ( -2016 were searched using the substance name term 'vemurafenib', the keywords 'vemurafenib', 'BRAF inhibitors' and melanoma', and the MeSH term 'neoplasms'. Additionally, abstracts containing the term 'vemurafenib' published by the American Society of Clinical Oncology for conferences held between 2010 and 2016 were manually searched.
Study selection
We considered for inclusion any studies meeting the following criteria: (i) human studies; (ii) prospective clinical trials and expanded-access (i.e. outside clinical trials) programmes; (iii) clinical investigations in patients with melanoma; (iv) assignment of patients to vemurafenib as monotherapy; and (v) data available for analysis of prevalence of dermatological toxicities.
Exclusion criteria
The exclusion criteria were as follows: (i) investigations in patients who did not have melanoma and (ii) original studies that did not meet the first criterion (i.e. did have patients with melanoma) but in which drugs other than vemurafenib were used, or in which vemurafenib was used with other drugs as polytherapy.
Data extraction
To understand the baseline of all included studies, we extracted the following information: trial design, number of patients enrolled, treatment information and characteristics of the participants. Next, all relevant data were extracted by two of the authors (PC and FC) using a standardized data extraction form. Differences were resolved through discussions with the third author (BZ).
The following dermatological events were regarded as clinical endpoints in our analysis according to the safety outcomes of clinical trials with regard to vemurafenib: cSCC, rash, PR, KA and HSFR. To analyse the prevalence of dermatological toxicities associated with vemurafenib, we collected data on the number of toxicity events (all-grade and high-grade; the later being grade 3 or above) associated with vemurafenib.
Definition of main outcomes
Severity of AEs was graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events (v4.0). High-grade AEs were defined as severe events, and graded as 3 or above. All-grade AEs included high-grade AEs plus all others of lower severity, thus all-grade AEs of cSCC, rash, PR, KA and HSFR were defined as these conditions graded as 1-5. 
Statistical analysis
Pooled prevalence estimates and 95% CIs, stratified by study setting and patient sex, were determined by random effects meta-analysis, with between-study heterogeneity assessed using I 2 statistic. Where available, adjusted prevalence estimates (e.g. by age) were used in the meta-analysis. If adjusted estimates were not reported, unadjusted estimates and exact 95% CIs were calculated from extracted data. We assessed the quality of study according to the Cochrane Handbook, taking into account randomization, allocation concealment, blinding, completeness of follow-up and dropout rate. Overall quality of studies was graded as A, B or C, with A having minimization of bias in all categories above; B having each of the criteria for grade A partially met; and C having one or more of the criteria for grade A not met. Meta-analysis was carried out using the R Meta package (v2.13.2).
Results
Study selection
Of the studies initially identified, we excluded reports that did not meet the inclusion criteria after first screening the study titles and abstracts. Finally, 11 relevant clinical trials comprising a total of 4197 patients were included in the meta-analysis; Fig. 1 illustrates how the 11 studies were obtained from the literature search. The 11 selected studies were published between 2012 and 2015. The main characteristics of the studies are listed in Table 1 , and the main results are shown in Table 2 .
Main adverse events
Cutaneous squamous cell carcinoma. Analysis of the prevalence of all-grade cSCC associated with heterogeneity in patients with melanoma was performed for eight studies. [7] [8] [9] 11, 12, [15] [16] [17] Testing for interstudy heterogeneity gave significant results [Q = 85.56; P < 0.01; I 2 = 91.8% (high heterogeneity was I 2 > 50%)]. The random-effects model meta-analysis indicated that the overall prevalence of all-grade cSCC was 18.00% (95% CI 0.12-0.26%) in patients assigned to vemurafenib (Fig. 2a) . High-grade cSCC associated with vemurafenib occurred in 489 of 3763 events in 3 trials; 8, 13, 16 overall prevalence of high-grade cSCC was 16.00% (95% CI 0.11-0.23%) and between-study heterogeneity was Q = 17.05 (P < 0.01; I 2 = 88.3) (Fig. 3a) .
Rash. Nine trials [8] [9] [10] 12, 13, [15] [16] [17] reported all-grade rash, which made up 2080 of 4111 events. The random-effects model showed that in patients treated with vemurafenib, overall prevalence of all-grade rash was 45.00% (95% CI 0.34-0.57) with Q = 123.88 (P < 0.01; I 2 = 92.7) (Fig. 2b) . Highgrade rash was reported in five trials 8, 9, 12, 13, 16 and occurred in 396 out of 4001 total events; overall prevalence of high-grade rash was 12.00% (95% CI 0.03-0.38) and Q = 495 (P < 0.01; I 2 = 99%) (Fig. 3b) . The results indicated that there is a significantly increased prevalence of all-grade rash associated with vemurafenib.
Three studies 8, 10, 12 reported all-grade maculopapular rash in patients treated with vemurafenib, with an overall prevalence of 15.00% (95% CI 0.07-0.28) by the random-effects model meta-analysis (Q = 10.03; P = 0.017; I 2 = 80.1%). Therefore, vemurafenib was associated with a significantly increased prevalence of both all-grade and high-grade rash in patients with melanoma.
Photosensitivity reaction. In total, 8 trials [8] [9] [10] [12] [13] [14] 16, 17 (4095 patients) were included in the meta-analysis for all-grade PR. Testing for interstudy heterogeneity gave Q = 52.67 (P < 0.01; I 2 = 86.75%), so we used the random-effects model for meta-analysis. The overall prevalence of all-grade PR was 30.00% (95% CI 0.23-0.38) in patients assigned to vemurafenib (Fig. 2c) . Five trials 8, 9, 12, 16, 17 reported high-grade PR, which occurred in 90 of 4022 events. As determined by the random-effects model (Q = 5.98; P < 0.01; I 2 = 83.5%), the overall prevalence of high-grade PR was 4.00% (95% CI 0.02-0.08) (Fig. 3c) .
Keratoacanthoma. In total, 7 trials 7-9,11,14,16,17 (4028 patients) reported all-grade KA. According to the random-effects model (Q = 37.75; P < 0.01; I 2 = 84.1%), the overall prevalence of all-grade KA was 10.00% (95% CI 0.06-0.15) in patients treated with vemurafenib (Fig. 2d) . Two trials 8, 16 reported high-grade KA (227 of 3742 events), and the fixed-effects model (Q = 0.24; P = 0.63; I 2 = 0) showed that use of vemurafenib did not increase the prevalence of highgrade KA (6.00%, 95% CI 0.05-0.07) (Fig. 3d) .
Hand-foot skin reaction. Two trials 12, 17 (173 patients) reported all-grade HFSR associated with vemurafenib, and the random-effects model meta-analysis (Q = 2.7; P = 0.01; I 2 = 63%) showed that the overall prevalence was 9.00% (95% CI 0.04-0.20) (Fig. 2e) . In Figure 1 Flow diagram of the study selection process. 
Publication bias
The rank correlation test and the estimated study number were used to quantitatively evaluate publication bias (Table 3) , and revealed that publication bias was not significant in confounding the overall prevalence of cSCC, rash, PR or KA (P > 0.05). The number of studies reporting high-grade KA and HFSR included all-grade and high-grade AEs, and were too small to conduct Begg test.
Discussion
Cutaneous AEs occurring during vemurafenib therapy are emerging issues for patients with melanoma. To our knowledge, our study is the first meta-analysis of clinical studies to assess prevalence of dermatological toxicities associated with vemurafenib, and we found that that vemurafenib is associated with high incidence and risk of dermatological toxicities such as cSCC, rash, PR, KA and HSFR. 18 cSCC is a frequent AE of vemurafenib treatment.
Vermuafenib-associated cSCC occurred in about 18% (95% CI 12.00-26.00%) of patients in the included trials. Studies have confirmed the molecular mechanisms of cSCC caused by vemurafenib; the heterodimers or homodimers of RAS isotypes in cells with wild-type BRAF are induced by BRAF inhibitors, then the mitogen-activated protein kinase (MAPK) pathway is activated. 19 It is thought that cSCC might be potentiated by vemurafenib from cells harbouring RAS mutations as pre-existing initiating oncogenic events. Although the molecular mechanisms underlying the dermatological toxicities associated with vemurafenib have been well studied, only a few studies have reviewed risk factors that might be related to the development of cSCC. 20 These factors might be useful for clinicians in the daily management of patients on vermurafenib. One study 15 reported that more than half of cSCCs developed in areas of the body with high sun exposure, reinforcing the hypothesis that vemurafenib induces cSCC in cells with specific molecular alterations (probably because of intense ultraviolet light exposure). Thus, appropriate steps to reduce the effect of such factors can be taken in order to improve daily clinical management of patients on vemurafenib.
The results of our meta-analysis showed that rash is the most common dermatological AE of vemurafenib, with an overall prevalence of 45.00% (95% CI 34.00-57.00%). Grade 1-2 toxicities are considered mild or moderate in severity and can usually be resolved with appropriate management. 21 We found the overall incidence of Grade 3-4 rash to be 12.00%, which indicates this to be a common cutaneous AE. Rash was reported as an erythematous eruption and desquamation of involved areas on the face, scalp and trunk. Studies have confirmed that the lesions of rash generally appear between 2 and 6 weeks after initiation of vemurafenib treatment. 22 In addition, one study 18 reported that grade 3-4 rashes were associated with cases of drug reaction with eosinophilia and systemic symptoms or acute generalized exanthematous pustulosis at 4 days after vemurafenib resumption at normal dose. Although the mechanism of erythema associated with vemurafenib is not yet clear, research into the possible role of vemurafenib in Raf inhibition is ongoing. 23 In the current study, rates of PR, which is also a common skin-related AE, were generally similar to those previously observed, 18 as shown in our metaanalysis, which found a rate of 30.00% (95% CI 23.00-38.00%). PR usually presents as erythema or congestive oedema on the skin surface after only a few hours of sun exposure. PR did not lead to dose reduction or treatment interruption. It has been suggested 20 that patients should avoid exposure to sunlight after taking vemurafenib.
KA is a well-differentiated skin cancer with low potential for invasive or metastatic disease. In our study, KA was present in 10.00% (95% CI 6.00-15.00%) of patients receiving vemurafenib. A number of previous studies have described the clinical and histological characteristics of KA reported in ª 2018 British Association of Dermatologists vemurafenib-treated patients, but the pathogenesis of KA is still unclear. 24 HFSR presents as numbness, insensitivity paraesthesia, tingling, swelling of the skin or erythema, desquamation, chapped skin, callous-like blisters or severe pain. 25 Clinical statistics shows that most cases of Grade 1-2 HFSR associated with vemurafenib can be prevented and controlled. It has been reported that the bilateral hands or feet of patients are usually affected, and that this usually occurs during the first 6 weeks of treatment. The severity and frequency of these symptoms are dose-related. 26 Patients with grade 1 HFSR vemurafenib may take appropriate measures such as dose modification according to the protocol or continue to use the original dosage with symptomatic relief. Patients with grade 2-3 HFSR should seek medical advice, and the dose should be reduced back to the original dose (960 mg twice daily). Vemurafenib-associated HFSR occurs predominantly on hyperkeratotic areas of the hands and feet that are subject to chronic pressure, whereas classic hand-foot syndrome is diffuse and less restricted to pressure areas. 27 The pathogenesis of HFSR associated with vemurafenib is still unclear at present, but its pathophysiological mechanism may be related to the direct toxic effect of vemurafenib in the areas affected, because of the high concentration of eccrine glands in the palms and soles. 28 It is very important to have adequate prevention and treatment for skin toxicities associated with vemurafenib in patients with melanoma, because pain and discomfort can be alleviated by suitable management. 29 The studies included in our meta-analysis discuss the management of cutaneous AEs, including measures such as topical therapies for symptom relief, dose modification and temporary interruption, or for severe cases, even permanent discontinuation of vemurafenib. 30 For grade 1 skin toxicity, it is recommended that patients should continue with vemurafenib as topical therapy to relieve symptoms. Vemurafenib used as topical therapy does not need to be discontinued when grade 2 toxicity occurs for the first time. 31 If the toxicity symptoms recur, the dose can be lowered, but it is not recommended to reduce it to below 480 mg. The first or second occurrence of grade 3 toxicity requires treatment interruption until toxicity resolves to grade 0-1, and discontinuance should be considered on the third occurrence. 32 In recent years, several randomized clinical trials have shown that combining a BRAF inhibitor with a MAPK kinase (MEK) inhibitor not only addresses the limitations of single-agent BRAF inhibitors but also improves the progression-free survival and overall survival compared with with BRAF inhibitors alone. 33, 34 Although combined BRAF and MEK inhibition is well tolerated in many patients, it is not devoid of side effects. Several clinical trials have reported that diarrhoea, anorexia, nausea and vomiting are common AEs frequently associated with the use of a combination of BRAF and MEK inhibitors in daily clinical practice, and these require early and appropriate management to avoid unnecessary dose reductions and temporary or permanent treatment discontinuations. 7, 35 Therefore, there is a need to characterize the features, incidence and relative risk of significant AEs to take adequate prevention and intervention steps promptly. 36 
Limitations
Our meta-analysis had several limitations. Because only 11 studies met our inclusion criteria, the small number of trials and the low quality of most of them may make the conclusions less convincing. Publication bias could not be completely excluded based on Begg test. 37 The researchers mostly based diagnosis of skin toxicities on the doctor's clinical judgement, and thus the same signs produced different opinions from different researchers. Finally, there was heterogeneity between studies in study protocol and vemurafenib doses, which could have led to significant heterogeneity in the data. 38 Therefore, large-scale and welldesigned studies are needed to confirm our results.
Conclusion
As a BRAF inhibitor, vemurafenib is associated with high risk of SCC, rash, PR, KA and HFSR during treatment for melanoma. Other skin reactions occurring in patients need further study to confirm whether they are related to vemurafenib. The most frequently occuring dermatological toxicity associated with vemurafenib in patients with melanoma is rash. 39 An association between survival and severity of skin toxicity has not been found, but mild or moderate skin toxicities can be manageable. Clinicians should be aware of the dermatological toxicities associated with vemurafenib to ensure the safety and efficacy of vemurafenib in melanoma treatment.
